Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen

7d ago

ATOS

PremiumPress Releases

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

21d ago

ATOS

PremiumThe Fly

Atossa Therapeutics, Quantum Leap announces initiation of I-SPY 2 trial

21d ago

ATOS

PremiumPress Releases

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

25d ago

ATOS

PremiumPress Releases

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

27d ago

ATOS

PremiumThe Fly

Atossa Therapeutics presents data from 40mg cohort of Phase 2 EVANGELINE trial

27d ago

ATOS

PremiumCompany Announcements

Navigating Choppy Waters: Atossa Therapeutics’ Struggle with Compliance Costs and Business Performance

1M ago

ATOS

More ATOS News >

YAG2 News on the Web

2024-04-15

Atossa Therapeutics announces breast cancer trial evaluating lead asset in combination with Eli Lill

Proactive Investors

Neutral

2024-04-15

Atossa Therapeutics announces breast cancer trial evaluating lead asset in combination with Eli Lill

Proactive Investors

Neutral

2024-04-15

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate in Women with ER+/HER2- Breast Cancer

Yahoo Finance

Neutral

2024-04-11

Atossa (ATOS) Reports Positive Results From EVANGELINE Study

Zacks

Neutral

2024-04-11

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

Yahoo Finance

Neutral

2024-04-10

Atossa Therapeutics Poised for Growth with Promising Breast Cancer Treatment

TipRanks News

Bullish

2024-04-09

Atossa Therapeutics reports positive data from breast cancer treatment trial

Proactive Investors

Neutral

2024-04-09

Atossa Therapeutics reports positive data from breast cancer treatment trial

Proactive Investors

Neutral

News Score - Last 7 Days

Neutral

DE:YAG2

Sector Average

Media Buzz

This Week3 articles

Weekly Average4.75 articles

News Sentiment

This Week50%

Sector Average62%

See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:YAG2’s Media Buzz Sentiment?

3 articles about DE:YAG2 were published this week. In an average week, 4.75 articles are published.

What is DE:YAG2’s weekly average amount of articles?

In an average week, 4.75 articles about DE:YAG2 are published.

What is DE:YAG2’s News Sentiment?

50% of articles about DE:YAG2 were positive this week, compared to its sector average of 62%.

Healthcare Stocks that are Trending in the News

ELVElevance Health

INSPInspire Medical Systems

CGEMCullinan Management

EWEdwards Lifesciences

MRNSMarinus

Showing the stocks with the most bullish news sentiment over the past week

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing